Advertisement

Migraine Treatment in Pregnancy and Lactation

  • Anne H. CalhounEmail author
Migraine and Beyond (R Cowan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Migraine and Beyond

Abstract

Purpose of Review

Since up to 40.9% of reproductive aged women have migraine—and reproductive-aged women often reproduce—it is essential that we have good information and guidelines regarding proper treatment of migraine during pregnancy and lactation.

Recent Findings

A review of articles published in the last year on the treatment of migraine during pregnancy and lactation found dishearteningly little. Nevertheless, this article will review the risk/safety information related to migraine treatment in both pregnancy and lactation, citing both new and less recent publications.

Summary

There is little if any formal research is being carried out on pharmacotherapy for migraine that occurs during pregnancy or lactation. This is likely due to two issues: (1) neurology offers little training in female sex hormones, while gynecology is a surgical field; (2) there is the ever-present concern of litigation if any bad outcome occurs, yet there is no designation of “legally safe” that can be applied to a drug’s use in pregnancy and lactation.

Keywords

Migraine Treatment Pregnancy Lactation 

Notes

Compliance with Ethical Standards

Conflict of Interest

The author declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Amundsen S, Øvrebø TG, Amble NM, Poole AC, Nordeng H. Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. Eur J Clin Pharmacol. 2016;72(12):1525–35. This article highlights the problem of inadequate authoritative guidance for treatment of migraine inpregnancy and lactation CrossRefPubMedGoogle Scholar
  2. 2.
    Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20:701–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Maggioni F, Alessi C, Maggino T, Zanchin G. Headache during pregnancy. Cephalalgia. 1997;17:765–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003;23:197–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and migraine during pregnancy and puerperium: the MIGRA-study. J Headache Pain. 2011;12:443–51.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Goldszmidt E, Kern R, Chaput A, Macarthur A. The incidence and etiology of postpartum headaches: a prospective cohort study. Can J Anaesth. 2005;52:971–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Wilson JG. Current status of teratology. In: Wilson JG, Fraser FC, editors. Handbook of teratology. New York: Plenum; 1977. p. 47.CrossRefGoogle Scholar
  8. 8.
    Jacobs LR. Prescription to over-the-counter drug reclassification. Am Fam Physician. 1998;57:2209–14.PubMedGoogle Scholar
  9. 9.
    Matt DW, Borzelleca JF. Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In: Witorsch RJ, editor. Reproductive toxicology. 2d ed. New York: Raven; 1995. p. 175–93.Google Scholar
  10. 10.
    Collins E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol. 1981;585(Suppl):57S–62S.Google Scholar
  11. 11.
    Bérard A, Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 2012;52(7):1085–93.CrossRefPubMedGoogle Scholar
  12. 12.
    • Thompson JM, Waldie KE, Wall CR, Murphy R, Mitchell EA. Associations between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 years. PLoS One. 2014;9:e108210.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    • Brandlistuen RE, Ystrøm E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and child neurodevelopment: a siblingcontrolled cohort study. Int J Epidemiol. 2013;42:1702–13.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    • Lie Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014;168:313–20.CrossRefGoogle Scholar
  15. 15.
    European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): minutes of the meeting on 5–8 May 2014. PRAC: Agendas, minutes and highlights [online], http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2014/06/WC500169468.pdf (2014).
  16. 16.
    Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327:368.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol. 2012;206:228.e1–8.CrossRefGoogle Scholar
  18. 18.
    • Edwards DR, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol. 2012;120:113–22.CrossRefPubMedGoogle Scholar
  19. 19.
    • Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG. 2013;120:948–59.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006;77:268–79.CrossRefPubMedGoogle Scholar
  21. 21.
    van Gelder MM, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One. 2011;6:e22174.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Pfaffenrath V, Rehm M. Migraine in pregnancy. What are the safest treatment options? Drug Saf. 1998;19:383–8.CrossRefPubMedGoogle Scholar
  23. 23.
  24. 24.
    Fox AW. Revised estimate for probability of successful outcome of pregnancy after sumatriptan exposure [letter]. Headache. 2004;44:842–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: What have we learned? Headache. 2009;49:1414–22.CrossRefPubMedGoogle Scholar
  26. 26.
    Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache. 2010;50(4):563–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache J Head Face Pain. 2015;55:490–501.CrossRefGoogle Scholar
  28. 28.
    • Calhoun AH, Ford S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache. 2007;47:1178–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Calhoun AH, Ford S, Finkel A, Kahn D, Mann JD. The prevalence and spectrum of sleep problems in women with transformed migraine. Headache. 2006;46(4):604-10.Google Scholar
  30. 30.
    American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776–89.CrossRefGoogle Scholar
  31. 31.
    • Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 9th ed. Philadelphia: Lippincott Wilkins and Williams; 2011.Google Scholar
  32. 32.
    • Hale TW. Medications and mothers’ milk. 16th ed. Amarillo: Hale Publishing; 2014.Google Scholar
  33. 33.
    Wojnar-Horton RE, Hackett LP, Yapp P, Dusci LJ, Paech M, Ilett KF. Distribution and excretion of sumatriptan in human milk. Br J Clin Pharmacol. 1996;41(3):217–21.CrossRefPubMedGoogle Scholar
  34. 34.
    David PS, Kling JM, Starling AJ. Migraine in pregnancy and lactation. Curr Neurol Neurosci Rep. 2014 Apr;14(4):439.CrossRefPubMedGoogle Scholar
  35. 35.
    Relpax (eletriptan hydrobromide) [product monograph]. Kirkland, QC: Pfizer; 2004.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Carolina Headache InstituteDurhamUSA
  2. 2.Departments of Psychiatry and AnesthesiologyUniversity of North CarolinaChapel HillUSA

Personalised recommendations